Last week the Senate Committee on Health, Education, Labor and Pensions held a hearing on the 340B Drug Pricing Program to discuss its growth and impact on patients.
Among other subjects, the committee reviewed the importance of the 340B program; the pharmaceutical manufacturers’ rebate program that begins in January; potential transparency reforms; ensuring that 340B entities do not receive duplicate drug discounts; revising the definition of a patient for a covered entity; and reforms involving the use of contract pharmacies.
Representatives from the Government Accountability Office, Congressional Budget Office (CBO), UCLA served on the hearing’s witness panel.
Go here to find the testimony of the witnesses and to view a video of the hearing.